Treatment of intestinal protozoan infections in children

Area of Science:

• Medical Parasitology
• Infectious Diseases
• Pharmacotherapy

Background:

• Intestinal protozoan infections are a major global health concern, causing significant morbidity and mortality, particularly in developing nations.
• Children are especially vulnerable to severe illness from these infections, which can manifest as acute or chronic diarrhea.
• In immunocompromised individuals, such as those with AIDS, these infections can become life-threatening.

Purpose of the Study:

• To provide an updated overview of the current pharmacotherapy for treating common intestinal protozoan infections.
• To highlight the importance of accurate diagnosis and effective treatment for improving patient outcomes and public health.
• To focus on pharmacologic interventions for amoebiasis and giardiasis.

Main Methods:

• Literature review of current pharmacotherapeutic options.
• Analysis of treatment guidelines and clinical trial data.
• Synthesis of information on drug efficacy and safety for key intestinal protozoan pathogens.

Main Results:

• Established pharmacologic agents remain the cornerstone of treatment for amoebiasis and giardiasis.
• Emerging resistance patterns and newer therapeutic strategies are discussed.
• The review covers a range of drugs effective against various intestinal protozoa.

Conclusions:

• Effective pharmacotherapy is crucial for managing intestinal protozoan infections and reducing associated morbidity and mortality.
• Timely diagnosis and appropriate treatment are essential for both individual patient care and broader public health initiatives.
• Continued research into novel treatments and resistance monitoring is warranted.